Autopsy report · NCT04982224
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Registered 4 months before it started.
- Ran for about 3 years 11 months before it stopped.
- 30 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Regeneron Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Advanced NSCLC
- Interventions
- REGN5093-M114; Cemiplimab
- Participants
- 30
- Sites
- 11
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.